MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells

Jichun Ma; Dehong Wu; Jing Yi; Yunyun Yi; Xin Zhu; Hongchun Qiu; Rong Kong; Jiang Lin; Jun Qian; Zhaoqun Deng

Biomedicine & Pharmacotherapy (Apr 2019)

MiR-378 promoted cell proliferation and inhibited apoptosis by enhanced stem cell properties in chronic myeloid leukemia K562 cells

Jichun Ma,
Dehong Wu,
Jing Yi,
Yunyun Yi,
Xin Zhu,
Hongchun Qiu,
Rong Kong,
Jiang Lin,
Jun Qian,
Zhaoqun Deng

Affiliations

Jichun Ma: Department of Central Lab, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China; The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, China
Dehong Wu: Department of Hematology, Kunshan Third People’s Hospital, KunShan, Jiangsu, China
Jing Yi: Department of Central Lab, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China; The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, China
Yunyun Yi: Department of Central Lab, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China; The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, China
Xin Zhu: Department of Central Lab, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China; The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, China
Hongchun Qiu: Department of Hematology, Kunshan Third People’s Hospital, KunShan, Jiangsu, China
Rong Kong: Department of Hematology, Kunshan Third People’s Hospital, KunShan, Jiangsu, China
Jiang Lin: Department of Central Lab, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China; The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, China
Jun Qian: Department of Central Lab, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China; The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, China; Corresponding author at: Department of Hematology, Affiliated People’s Hospital of Jiangsu University, 8 Dianli Road, 212002, Zhenjiang, China.
Zhaoqun Deng: Department of Central Lab, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China; The Key Lab of Precision Diagnosis and Treatment in Hematologic Malignancies of Zhenjiang City, China; Corresponding author at: Laboratory Center, Affiliated People’s Hospital of Jiangsu University, 8 Dianli Road, 212002, Zhenjiang, China.

Journal volume & issue: Vol. 112

Abstract

Read online

Dysregulation of miR-378 has been found in diverse types of tumors as well as in leukemia. The role of miR-378 in chronic myeloid leukemia (CML) remains unclear. The aim of the study was to reveal the potential effects of miR-378 in the pathological process and progress in CML. Our results showed general level of miR-378 was significant higher in CML patients compared to controls. Overexpression of miR-378 dramatically promoted cell proliferation and drug-resistance. Additionally, apoptosis was inhibited in cells transfected with miR-378. More and bigger stem cell sphere formation was observed in miR-378 transfected cells. Furthermore, enhanced expression of miR-378 was associated with upregulation of stem-cell makers OCT4 and c-Myc. Further study validated that miR-378 inhibited the expression of FUS1. Our research demonstrated the oncogenic nature of miR-378 in CML, and might contribute to the progress of CML.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords